-
Mashup Score: 0Novartis-partnered DARPin flames out in COVID-19 study, sending Molecular Partners' stock into nosedive - 3 year(s) ago
ACTIV-3 has claimed yet another victim. Molecular Partners and Novartis are the latest companies to fail to clear the efficacy bar in the NIH-sponsored COVID-19 study, leaving their hopes for ensovibep resting on a separate trial in non-hospitalized patients.
Source: FierceBiotechCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 3
Stryker inked a $3 billion deal to dramatically reshape its digital patient outreach efforts with the acquisition of Vocera Communications.
Source: FierceBiotechCategories: Cardiologists, Latest HeadlinesTweet-
Stryker ponies up $3B to buy Vocera and amp up its digital communications https://t.co/VDrDm0XCrU
-
RT @dlschermd: Stryker ponies up $3B to buy Vocera and amp up its digital communications https://t.co/VDrDm0XCrU
-
-
Mashup Score: 0
Just like its approval request for a phase 2 ALS drug, Amylyx Pharmaceuticals is once again skirting convention and going forward with an initial public offering when the biotech market appears to be dipping.
Source: FierceBiotechCategories: Latest Headlines, Rare DiseaseTweet-
After FDA U-turn, Amylyx eyes IPO to support ALS drug filings across the world https://t.co/3HNrwPQIqw
-
-
Mashup Score: 5'Day job and a gay job': LGBTQ+ leaders in biopharma want those who look, talk and love like them to be seen and counted - 3 year(s) ago
Organizations for LGBTQ+ biopharma employees are popping up in Boston, San Francisco, New York, New Jersey, Dublin and elsewhere. Companies are also working to build up their internal networks as LGBTQ+ employees want to see those who look, talk and love like them.
Source: FierceBiotechCategories: Cardiologists, Latest HeadlinesTweet-
And so proud of Austin for this beautiful piece in Fierce Biotech ❤️🌈 “LGBTQ+ leaders in biopharma want those who look, talk and love like them to be seen and counted” A must read! ⬇️ https://t.co/OMkr0jRSt1
-
-
Mashup Score: 0
Abbott gave $1 million to Howard University as part of the pharma giant’s efforts to diversify clinical trials by providing scholarships to medical students interested in pursuing the field of clinical research.
Source: FierceBiotechCategories: Healthcare Professionals, Latest HeadlinesTweet-
Abbott gifts $1M to @HowardU in effort to diversify clinical trials | @FierceBiotech https://t.co/qaazXFV1Yu #DC #HBCU #pharma
-
-
Mashup Score: 0'Don't check yourself when you come to work': Being openly LGBTQ+ in a scientist-led industry - 3 year(s) ago
Biopharma leaders share their stories of coming out over the decades and what it means to have out members of the community in the top echelons of drug development. But being out shouldn’t be a prerequisite for fostering safe, welcoming workplaces.
Source: FierceBiotechCategories: Future of Medicine, Latest HeadlinesTweet-
Thank you to our own Kristy Birchard for talking so openly & authentically alongside other Biopharma LGBTQ+ members with @FiercePharma. They discussed how removing assumptions regarding people's identities can lead to truly diverse clinical trials. Read: https://t.co/I8YC7bJZoV
-
-
Mashup Score: 1
Philips is looking to bolster its vascular franchise by absorbing Vesper Medical, maker of stents designed to open up blocked or narrowed veins in the legs.
Source: FierceBiotechCategories: Future of Medicine, Latest HeadlinesTweet-
Philips gets the blood flowing with Vesper Medical vascular tuck-in buy #venous #stent #IVUS via @FierceBiotech https://t.co/WmFJZ1lbP8
-
-
Mashup Score: 0The top 10 M&A targets in medtech for 2022 - 3 year(s) ago
Even as 2021 looks to be a landmark year for medtech M&A, all signs point to 2022’s tally dwarfing this year’s. M&A trends for 2022 will likely shake out into two broad categories: larger players looking for bolt-on deals and mid-size companies wanting to consolidate. And when it comes to who’s buying, the short answer is: everyone.
Source: FierceBiotechCategories: Healthcare Professionals, Latest HeadlinesTweet-
The top 10 #MnA targets in #medtech for 2022 https://t.co/pbxafvaO7c https://t.co/wzegQrhV4A
-
-
Mashup Score: 1GlaxoSmithKline, University of Oxford join forces in $40M digital deep dive into neuro - 3 year(s) ago
Major U.K. Big Pharma GlaxoSmithKline and leading academic center the University of Oxford have penned a five-year research deal focused on making smarter bets on so-called “digital biology.”
Source: FierceBiotechCategories: Cardiologists, Latest HeadlinesTweet-
RT @davidbriess: GlaxoSmithKline, University of Oxford join forces in $40M digital deep dive into neuro https://t.co/fIpd6OgTWB
-
-
Mashup Score: 3Insilico Medicine begins first human trial of its AI-designed drug for pulmonary fibrosis - 3 year(s) ago
The former Fierce 15 winner announced that the first healthy volunteer in an Australian study has received a limited, intravenous dose of the company’s ISM001-055, a small-molecule inhibitor aimed at the chronic lung disease.
Source: FierceBiotechCategories: Future of Medicine, Latest HeadlinesTweet-
AAIH Member Spotlight: @InSilicoMeds has launched their first trial in humans for their #AI-designed drug for #pulmonaryfibrosis. Congratulations!🎉 Learn more about their work here: https://t.co/gz4N0Nc7ZO #artificialintelligence #aihealthcare #AAIH
-
7/ thoughts? This appears pretty good. More options are needed. This same #ensovibep did not work in NIH #activ3 trial when tested among hospitalized patients. Same paradigm holds, anti-virals role is for early treatment. >7d = too late https://t.co/ZhpuGp2DEf